Vytrus Biotech grows unstoppable. The company specialized in active ingredients derived from plant biotechnology dedicated to the cosmetic industry has increased its sales by 41% and its net profit by 81% during the first quarter of 2026, compared to the same period of the previous year, it reported in a statement this Tuesday.
Vytrus' sales in the last 12 months stand at 9.25 million euros, which, coupled with "a rigorous management of operating costs," has allowed Vytrus to increase its EBITDA by 67% compared to the same period in 2024, reaching the figure of 1.71 million; the EBITDA margin as of March 2026 stands at 56.9% (48% in 2025).
Vytrus has thus increased its net profit by 81% compared to 2025, reaching 1.2 million euros "thanks to the good performance of the business".
Sales growth is mainly located in the European Union, including Spain, where they increased by 73% compared to the same period of 2025, while the U.S. closed with a slight reduction of -3% compared to the first quarter of 2025, derived from the delicate economic situation of the world's leading economy.
The Asia-Pacific region closed the first quarter with a reduction of -25% due to the slower market evolution in India, and the Latin America area also started the year at a slower pace and ended with a reduction of -42% compared to 2025; invoicing in the rest of the world increased by 57% in the first quarter with very good performance from the United Kingdom.